Blindspot by GroundNews BioNTech to Buy CureVac for $1.25 Billion to Boost Cancer Arm Published 22 hours ago on June 13, 2025 By The Janitor BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. Related Topics: Up Next EU Rights Court Says Italy Not Responsible for Libyan Coast Guard Actions over Migrant Boat Sinking Don't Miss UN agencies say a violence-hit part of South Sudan is on the brink of famine The Janitor Continue Reading You may like Click to comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Type in the text displayed above Δ{{#message}}{{{message}}}{{/message}}{{^message}}Your submission failed. The server responded with {{status_text}} (code {{status_code}}). Please contact the developer of this form processor to improve this message. Learn More{{/message}}{{#message}}{{{message}}}{{/message}}{{^message}}It appears your submission was successful. Even though the server responded OK, it is possible the submission was not processed. Please contact the developer of this form processor to improve this message. Learn More{{/message}}Submitting…
